Smoking Cessation and Alcohol Use Among Cancer Survivors: Investigating the Efficacy of a Mindfulness-Based Intervention

What this Trial Is About

Researchers are evaluating the effectiveness of Mindfulness-Based Relapse Prevention for Smoking and Alcohol (MBRP-SA) compared to standard care among cancer survivors who smoke and engage in risky alcohol use. The study aims to test how well MBRP-SA works, explore factors that may influence its effects, and assess how it can be implemented in medical and community settings in Florida. The research includes interviews with stakeholders and a cost-effectiveness analysis of both treatment approaches. Participants are randomly assigned to one of two groups. One group receives the MBRP-SA program, a nine-week group mindfulness intervention delivered via Zoom, designed to help reduce smoking and heavy drinking by addressing cravings, stress, and habits. They also receive 10 weeks of nicotine replacement therapy. The other group is connected to the Florida Tobacco Quitline for phone-based counseling and resources for smoking cessation, including up to four weeks of nicotine replacement therapy, along with referrals to community alcohol treatment services. During the study, researchers will assess smoking abstinence and alcohol use six months after treatment using biochemical confirmation and self-reporting of heavy drinking days. Participants will have group sessions and access to counseling or resources depending on their assigned group. The study monitors progress, collects data through interviews, and evaluates outcomes to understand the impact of these approaches. The study is sponsored by H. Lee Moffitt Cancer Center and Research Institute and will continue through 2029.

Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors